ArticleFrontiers in human neuroscience2018
Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring.
Article in Frontiers in human neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 64 citations in OpenAlex.
- A pilot study of alternative substrates in the critically Ill subject using a ketogenic feed.Nature communications · 2023Trial
- Differential Expression of Human and Bacterial Proteins Reveals Microbiome-Host Crosstalk in Metabolic Disorders.Proteomics. Clinical applications · 2026Article
- Alterations in brain metabolites in rats with experimental periodontitis: A metabolomic approach.Journal of periodontology · 2026Article
- Dynamic alterations and potential roles of gut microbiota and metabolites in Angiostrongylus cantonensis-infected mice and rats.Infectious diseases of poverty · 2026Article
- Unraveling the Matrix: Proteomic Profiling Reveals Stromal ECM Dysregulation in Severe Early-Onset Fetal Growth Restriction.International journal of molecular sciences · 2025Article
- The Serum Lipid Profile of Relapsing Multiple Sclerosis Differs Reproducibly From Healthy Controls.Journal of neurochemistry · 2025Article
- Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.International journal of molecular sciences · 2025Review
- The Erythrocyte Fatty Acid Profile in Multiple Sclerosis Is Linked to the Disease Course, Lipid Peroxidation, and Dietary Influence.Nutrients · 2025Article
- Raman liquid biopsy: a new approach to the multiple sclerosis diagnostics.Frontiers in neurology · 2025Article
- Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis.Metabolites · 2024Review
- Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity.iScience · 2024Article
- Association of multiple sclerosis with stroke: A comprehensive review.Health science reports · 2024Article
- Dysregulation of humoral immunity, iron homeostasis, and lipid metabolism is associated with multiple sclerosis progression.Multiple sclerosis and related disorders · 2023Article
- Metabolite Alterations in Autoimmune Diseases: A Systematic Review of Metabolomics Studies.Metabolites · 2023Review
- Metabolic fingerprint of patients showing responsiveness to treatment of septic shock in intensive care unit.Magma (New York, N.Y.) · 2023Article
- The Transport and Uptake of Resveratrol Mediated via Glucose Transporter 1 and Its Antioxidant Effect in Caco-2 Cells.Molecules (Basel, Switzerland) · 2023Article
- Metabolomic profiles in relapsing-remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Seasonal Changes in Serum Metabolites in Multiple Sclerosis Relapse.International journal of molecular sciences · 2023Article
- Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis.Frontiers in genetics · 2023Review
- Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances.Biomedical journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary progressive multiple sclerosis (PPMS) shows a highly variable disease progression with poor prognosis and a characteristic accumulation of disabilities in patients. These hallmarks of PPMS make it difficult to diagnose and currently impossible to efficiently treat. This study aimed to identify plasma metabolite profiles that allow diagnosis of PPMS and its differentiation from the relapsing-remitting subtype (RRMS), primary neurodegenerative disease (Parkinson's disease, PD), and healthy controls (HCs) and that significantly change during the disease course and could serve as surrogate markers of multiple sclerosis (MS)-associated neurodegeneration over time. We applied untargeted high-resolution metabolomics to plasma samples to identify PPMS-specific signatures, validated our findings in independent sex- and age-matched PPMS and HC cohorts and built discriminatory models by partial least square discriminant analysis (PLS-DA). This signature was compared to sex- and age-matched RRMS patients, to patients with PD and HC. Finally, we investigated these metabolites in a longitudinal cohort of PPMS patients over a 24-month period. PLS-DA yielded predictive models for classification along with a set of 20 PPMS-specific informative metabolite markers. These metabolites suggest disease-specific alterations in glycerophospholipid and linoleic acid pathways. Notably, the glycerophospholipid LysoPC(20:0) significantly decreased during the observation period. These findings show potential for diagnosis and disease course monitoring, and might serve as biomarkers to assess treatment efficacy in future clinical trials for neuroprotective MS therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.